search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


• Research study to investigate the safety, tolerability and effects of multiple doses of LTI-291 in patients with Parkinson’s Disease with a GBA1 mutation.


- candidate number28446
- NTR NumberNTR6960
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR17-jan-2018
- Secondary IDsCHDR1710  NL62049.056.17 / 2017-004086-27 / LTI-291-003
- Public Title• Research study to investigate the safety, tolerability and effects of multiple doses of LTI-291 in patients with Parkinson’s Disease with a GBA1 mutation.
- Scientific Title• A Randomized, Placebo-Controlled, Double-Blind, Parallel Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of LTI-291 in Patients with Parkinson’s Disease and a GBA1 Mutation
- ACRONYM• First-In-Patient study of LTI-291
- hypothesis• To evaluate the safety and tolerability of three oral dose levels of LTI-291 following 28 days of LTI-291 treatment in patients with Parkinson’s Disease with GBA-PD.
• To characterize the plasma and CSF pharmacokinetics (PK) of LTI-291 following 28 days of LTI-291 treatment in patients with GBA-PD.
• To evaluate the pharmacodynamics of LTI-291 following 28 days of treatment in patients with GBA-PD using biomarker assessments.
- Healt Condition(s) or Problem(s) studiedParkinson's disease, Movement disorders, GBA1 mutation
- Inclusion criteria1. Signed informed consent prior to any study-mandated procedure.
2. Minimum age of 18 years.
3. Clinical diagnosis of Parkinson’s Disease at least 6 months prior to screening, confirmed by a neurologist.
4. A score of 1-4 on Hoehn & Yahr Scale.
5. Mutation(s) in glucocerebrosidase GBA1 gene.
6. Mini Mental State Exam score >/= 18 and assessed by the investigator or qualified designee as able to provide informed consent.
7. Body mass index (BMI) between 18 and 35 kg/m2, inclusive, and with a minimum weight of 45 kg at screening.
8. All females must be at least 2 years post-menopausal or surgically sterile or practice highly effective contraception until at least 90 days after their last dose of study treatment.
9. All males must practice effective contraception and abstain from sperm donation during the study and be willing and able to continue contraception for at least 90 days after their last dose of study treatment.
10. Has the ability to communicate with the investigator and is willing to comply with the study restrictions.
- Exclusion criteria1. Any active or chronic disease or condition other than PD that could interfere with, or for which the treatment might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator (following medical history review, physical examination, vital signs (supine systolic and diastolic blood pressure, pulse rate, body temperature), 12-lead electrocardiogram (ECG), and clinical laboratory parameters (hematology, blood chemistry, and urinalysis)). Minor deviations of laboratory values from the normal range may be accepted, if judged by the investigator to have no clinical relevance.
2. History of recent major surgery (within 60 days of screening) that could interfere with, or for which the treatment might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator.
3. Atypical or secondary parkinsonism by medical history or in the opinion of the investigator. Atypical parkinsonism includes, but not limited to a diagnoses of progressive supranuclear palsy, corticobasal syndrome and multiple system atrophy. Secondary parkinsonism includes drug-induced, post-infectious, post-traumatic and vascular parkinsonism.
4. Patients that experience Freezing Of Gait (FOG) in the on-state of L-dopa treatment (paradoxical response), which might interfere with the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator.
5. Current (within last 30 days prior to start of clinical phase) use of a strong CYP3A4 modulator. Reference Appendix B for a list of prohibited CYP3A4 modulators.
6. Current use of any drug known to significantly inhibit blood coagulation in the opinion of the investigator.
7. Vaccination within 7 days prior to start of dosing.
8. Any contra-indication for undergoing a lumbar puncture procedure (e.g. anatomical variations or local skin infection).
9. Positive Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening.
10. Participation in an investigational drug or therapeutic device study within 3 months prior to first dosing, or within 6 months for a biologic investigational product.
11. Recent history (last 6 months) of abuse of addictive substances (alcohol, illegal substances) or current use of more than 21 units of alcohol per week, drug abuse, or regular recreational user of sedatives, hypnotics, tranquillizers, or any other addictive agent.
12. Positive test for drugs of abuse at screening or pre-dose.
13. Women currently pregnant or breastfeeding.
14. Loss or donation of blood over 500 mL within three months (males) or four months (females) prior to screening or intention to donate blood or blood products during the study.
15. Any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 18-dec-2017
- planned closingdate30-jun-2018
- Target number of participants40
- Interventions• LTI-291 and placebo
- Primary outcome• Safety and tolerability endpoints
- Secondary outcome• Functional outcome measures
• Pharmacokinetic endpoints
• Pharmacodynamic endpoints
- Timepoints• Screening (up to 30 days before study start); demographics / physical examination / blood sampling / vital signs / ECG / Alcohol breath test / neurocart training
• Day -1 (admission to the clinic) ; Physical / blood sampling / urine collection, ECG / vital signs / CSF sampling / EEG / neurocart
• Day 0 : Vitals / dosing / blood sampling / ECG / discharge
• Day 6 & 13 : vitals / blood sampling / urine collection / ECG and neurocart (only on day 13).
• Day 20: telephone follow up
• Day 26 : admission to the clinic if applicable
• Day 27 : Blood sampling / urine collection / dosing / CSF sample / Vitals / ECG / Alcohol breath test / EEG/ discharge if applicable
• Day 38 (Follow up visit) ; physical examination, blood sampling, vital signs /alcohol breath test
- Trial web siteNA
- statusstopped: trial finished
- CONTACT FOR PUBLIC QUERIESMD, PhD Geert Jan Groeneveld
- CONTACT for SCIENTIFIC QUERIESMSc Annelieke Kruithof
- Sponsor/Initiator Lysosomal Therapeutics Incorporated
- Funding
(Source(s) of Monetary or Material Support)
Lysosomal Therapeutics Incorporated
- PublicationsNA
- Brief summary• Approximately 10% of patients with clinically diagnosed Parkinson’s disease, Lewy Body Dementia, or Diffuse Lewy Body disease have a GBA1 mutation. More recently, it has become clear that even carrying one mutated allele of GBA1 significantly increases the lifetime risk of developing parkinsonism. Existing treatments are symptomatic in nature, and do not modify the underlying disease progression. For patients with GBA-PD, some approaches eg DBS and anti-cholinergic agents may be contra-indicated due to the risk of worsened cognitive decline (Sasagasako et al., 1994; Thaler et al., 2017). Therapies targeting underlying pathogenesis could slow disease progression in this population. Several lines of evidence suggest that activation of GCase enzymatic activity could provide therapeutic benefit to patients carrying a heterozygous mutation in the GBA1 gene. The GCase activator, LTI-291 could be a potential treatment for patients with GBA-PD. All participants will be recruited in the Netherlands
- Main changes (audit trail)
- RECORD17-jan-2018 - 15-sep-2018


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl